The MoBot Report

October 28, 2024

DENVER, Colo., Oct 28, 2024 (247marketnews.com)- MoBot’s recent alerts involved; Monte Rosa (NASDAQ: GLUE), Novartis (NYSE: NVS), Trump Media (NASDAQ: DJT), Evoke Pharma (NASDAQ: EVOK), Autonomix Medical (NASDAQ: AMIX), and Bright Minds (NASDAQ: DRUG).

MoBot posted Monte Rosa Therapeutics (NASDAQ: GLUE) at $7.067 and $6.27 this morning, following the news that Monte Rosa entered a global exclusive development and commercialization license agreement with Novartis (NYSE: NVS)  to advance VAV1 MGDs, including MRT-6160, an orally bioavailable investigational degrader of VAV1, a key signaling protein downstream of both the T- and B-cell receptors, which is in an ongoing Phase 1, single ascending dose (SAD)/multiple ascending dose (MAD) healthy volunteer study for immune-mediated conditions.

It took a while, but Monte Rosa is trading above $10, on the news.

MoBot alerted Trump Media (NASDAQ: DJTWW) on September 24 at $7.818 and it hit $36 today, flowing Trump’s Madison Square Garden rally and November election data.

MoBot liked Evoke Pharma’s (NASDAQ: EVOK) response to the news that it and EVERSANA presented data from a real-world retrospective study evaluated the impact of GIMOTI (metoclopramide nasal spray) in patients with diabetic gastroparesis (DGP) who were concurrently using GLP-1 receptor agonist, at the American College of Gastroenterology (ACG) 2024 Annual Meeting.

Evoke Pharma this morning at $10.568 and it hit a high of $17.39, just before the open, but it hasn’t been able to match that performance in the regular trading session.

Autonomix Medical (NASDAQ: AMIX) alerted Mobot, following its reported positive preliminary results from the first five “lead-in” patients in the Company’s ongoing proof-of-concept human clinical trial evaluating the safety and effectiveness of delivering transvascular energy to ablate relevant problematic nerves and mitigate pain in patients with pancreatic cancer pain, with 100% of the responder group reaching zero opioid use at 4-6 weeks post-procedure.

Autonomix alerted at $10.819 and it raced to a high of $21.49 and it’s still significantly higher than Friday’s closing price.

Bright Minds (NASDAQ: DRUG), which MoBot alerted at $1.426, on Oct 14, before it ran to a new 52-week high of $79.02, continues to trade around the $50 level.

Bright Minds (NASDAQ: DRUG) stated, last week, that it is again collaborating with Firefly Neuroscience (NASDAQ: AIFF) to thoroughly evaluate the electroencephalogram (EEG) data in Bright Minds’ BREAKTHROUGH study, an open-label Phase 2 clinical trial evaluating the safety, tolerability, and efficacy of BMB-101, in adult patients with classic Absence Epilepsy and Developmental Epileptic Encephalopathy (DEE).

Please go to 247marketnews.com to sign up for free MoBot alerts and view Mobot’s real time data.

About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.

24/7 MARKET NEWS, INC Disclaimer
Please go to https://247marketnews.com/disclaimer/ for disclaimer information.

CONTACT:
24/7 Market News
Editor@247marketnews.com

Related news for (GLUE, NVS, DJT, EVOK, AMIX, DRUG)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.